Skip to main content
Clinical Trials/NCT02336568
NCT02336568
Unknown
Phase 4

The Effect of 21-Days Intranasal Oxytocin on Clinical Symptoms and Social Function in Patients With Post Traumatic Stress Disorder (PTSD), a Randomized Controled Trail

Rambam Health Care Campus0 sites40 target enrollmentMarch 2015
ConditionsPTSD
InterventionsPLACEBOOxytoine

Overview

Phase
Phase 4
Intervention
PLACEBO
Conditions
PTSD
Sponsor
Rambam Health Care Campus
Enrollment
40
Primary Endpoint
Semi-structured interviews (CAPS)and self-report questionnaires that examine the symptoms of the disorder and related symptoms (social function and aggressive behavior)
Last Updated
11 years ago

Overview

Brief Summary

Oxytocin (OT) - a neurohormone and neuromodulator which is mainly synthesized in the hypothalamus - is a mediator stress regulation and improves social bonding. Recently, several theoretical studies suggested that PTSD patients have abnormal functioning of the OT system. According to these theories, dysfunction in the oxytocin system may modulate the interpersonal impairment that characterizes PTSD, and therefore intranasal OT may potentially relieve these symptoms. In two current studies that were conducted in Rambam health care we found that a single dose of intranasal OT reduces anxiety and irritability symptoms, and enhances emotional empathy and compassion, in patients with PTSD. The main goal of this study is to examine the effects of 21-days intranasal Oxytocin on clinical symptoms and social function in these patients.

Detailed Description

This study will examine the effect is of 21-days intranasal Oxytocin on clinical symptoms and social function in these patients, in a double blind (treatment/placebo) study design.

Registry
clinicaltrials.gov
Start Date
March 2015
End Date
March 2018
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • PTSD patients (DSM-IV criteria)
  • Ability to provide written informed consent

Exclusion Criteria

  • Suicidality
  • Psychosis
  • Borderline Personality
  • Arrhythmia
  • Cardiac disease (arrythmia, heart failure)
  • Hyponatremia
  • Hypertension
  • Severe renal insufficiency
  • Liver cirrhosis
  • Lactating or pregnant women, or undergoing fertility treatment

Arms & Interventions

Placebo treatments

Other: Placebo treatments- 20 PTSD patients

Intervention: PLACEBO

intervention

intervention: Oxytoine treatments - 20 PTSD patients

Intervention: Oxytoine

Outcomes

Primary Outcomes

Semi-structured interviews (CAPS)and self-report questionnaires that examine the symptoms of the disorder and related symptoms (social function and aggressive behavior)

Time Frame: 3 weeks

Similar Trials